Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 19, Issue 6, 2013, Pages 586-589

  Malek, Naveed M ^a   Grosset, Katherine A ^a   Stewart, David ^b   Macphee, Graeme J A ^a   Grosset, Donald G ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b New Victoria Hospital ^*  (United Kingdom)

Author keywords

Arrhythmia; Citalopram; Domperidone; Parkinson's disease; QT interval

Indexed keywords

ALFUZOSIN; AMANTADINE; AMITRIPTYLINE; CIPROFLOXACIN; CITALOPRAM; CLARITHROMYCIN; DOMPERIDONE; DOSULEPIN; ERYTHROMYCIN; ESCITALOPRAM; FLUOXETINE; LITHIUM SALT; PAROXETINE; QUETIAPINE; SERTRALINE; SOLIFENACIN; SOTALOL; TRAZODONE; TRIMETHOPRIM; VENLAFAXINE; ANTIPARKINSON AGENT; PRESCRIPTION DRUG;

AGE DISTRIBUTION; AGED; ARTICLE; COMORBIDITY; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; HEART CONDUCTION; HUMAN; IATROGENIC DISEASE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; AGE; CHEMICALLY INDUCED DISORDER; HEART ARRHYTHMIA; LONG QT SYNDROME; MIDDLE AGED; CHEMICALLY INDUCED;

AGE FACTORS; AGED; ANTIPARKINSON AGENTS; ARRHYTHMIAS, CARDIAC; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PARKINSON DISEASE; PRESCRIPTION DRUGS;

EID: 84891501586     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.02.004     Document Type: Article

References (29)

1. Chaudhuri K., Schapira A. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-474.
2. van Noord C., Dieleman J., van Herpen G., Verhamme K., Sturkenboom M. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf 2010, 33:1003-1014.
3. Johannes C., Varas-Lorenzo C., McQuay L., Midkiff K., Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf 2010, 19:881-888.
4. Citalopram and escitalopram: QT interval prolongation - new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Drug Saf Update 2011, 5:A1.
5. Domperidone: small risk of serious ventricular arrhythmia and sudden cardiac death. Drug Saf Update 2012, 5:A2.
6. Schouten E., Dekker J., Meppelink P., Kok F., Vandenbroucke J., Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991, 84:1516. 23.
7. Soliman E., Howard G., Cushman M., Kissela B., Kleindorfer D., Le A., et al. Prolongation of QTc and risk of stroke: the REGARDS (reasons for geographic and racial differences in stroke) study. J Am Coll Cardiol 2012, 59:1460-1467.
8. Dekker J., Crow R., Hannan P., Schouten E., Folsom A. ARIC Study. Heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study. J Am Coll Cardiol 2004, 43:565-571.
9. Resources for professionals: QT drug lists by risk group [Internet]. Tucson (AZ): Arizona Center for Education & Research on Therapeutics. Available from: [accessed 25.07.12.]. http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm.
10. FDA talk paper: FDA warns against women using unapproved drug, domperidone, to increase milk production. Available from: [accessed 25.07.12.]. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm173886.htm.
11. Straus S., Sturkenboom M., Bleumink G., Dieleman J., van der Lei J., de Graeff P., et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005, 26:2007-2012.
12. Heath Canada. Drug and health products. Public communication. Available from: [accessed 25.07.12.]. http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2012/domperidone_pc-cp-eng.php.
13. U.S. food and drug administration safety update 2011. Available from: [accessed 04.08.12.]. http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm#data.
14. Classification of in vivo inhibitors of CYP enzymes, FDA. Available from: [accessed 04.08.12.]. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm.
15. Benoit S., Mendelsohn A., Nourjah P., Staffa J., Graham D. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005 Aug, 12(4):363-368.
16. Citalopram and CYP2C19 drug interactions. Pharmacy Administration Group Health Cooperative. Available from: [accessed 04.08.12.]. https://provider.ghc.org/open/caringForOurMembers/pharmacy/citalopram.pdf.
17. Drug analysis print. Medicines Health Regulatory Authority, UK. Available from: [accessed 04.08.12.]. http://www.mhra.gov.uk/home/groups/public/documents/sentineldocuments/dap_1343131440668.pdf.
18. Ziemssen T., Reichmann H. Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci 2010, 289:74-80.
19. Shibata M., Morita Y., Shimizu T., Takahashi K., Suzuki N. Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci 2009, 276:79-83.
20. Schoffer K., Henderson R., O'Maley K., O'Sullivan J. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007, 22:1543-1549.
21. Merello M., Pirtosek Z., Bishop S., Lees A. Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine. Clin Auton Res 1992, 2:215-219.
22. Woodford H., Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord 2005, 20:1104-1108.
23. Browne K., Prystowsky E., Heger J., Chilson D., Zipes D. Prolongation of the QT interval in man during sleep. Am J Cardiol 1983, 52:55-59.
24. Morganroth J., Brozovich F., McDonald J., Jacobs R. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991, 67:774-776.
25. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999, 354:1625-1633.
26. Ben-Shlomo Y., Churchyard A., Head J., Hurwitz B., Overstall P., Ockelford J., et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998, 316:1191-1196.
27. Ishizaki F., Harada T., Yoshinaga H., Nakayama T., Yamamura Y., Nakamura S. Prolonged QTc intervals in Parkinson's disease - relation to sudden death and autonomic dysfunction. No To Shinkei 1996, 48:443-448. [in Japanese].
28. Oka H., Mochio S., Sato H., Katayama K. Prolongation of QTc interval in patients with Parkinson's disease. Eur Neurol 1997, 37:186-189.
29. Deguchi K., Sasaki I., Tsukaguchi M., Kamoda M., Touge T., Takeuchi H., et al. Abnormalities of rate-corrected QT intervals in Parkinson's disease - a comparison with multiple system atrophy and progressive supranuclear palsy. J Neurol Sci 2002, 199(1-2):31-37.